| Hans-Günter Meyer-Thompson | Naloxon
USA. FDA approves naloxone injection to counteract opioid overdoses
USA. FDA approves naloxone injection to counteract opioid overdoses
Action: FDA has approved ZIMHI (naloxone hydrochloride) injection as an additional option to treat opioid overdose. ZIMHI is administered using a single-dose, prefilled syringe that delivers 5 milligrams (mg) of naloxone hydrochloride solution through intramuscular (in the muscle) or subcutaneous (under the skin) injection.
FDA has previously approved injectable naloxone hydrochloride products in 0.4 mg and 2 mg doses under the trade name, NARCAN. (FDA – US Food and Drug Administration, USA, 18.10.2021)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-naloxone-injection-counteract-opioid-overdoses